HTGM - HTG Molecular Diagnostics slips on $7.5M private placement

HTG Molecular Diagnostics (NASDAQ:HTGM) has slipped -7.08% pre-market on announcing a $7.5M private placement. The life science company entered into a definitive securities purchase agreement with a leading healthcare investor to sell 3,244,987 units at a price of $2.312/unit to the investor (less $0.001 for each pre-funded warrant purchased in lieu of a share of common stock). Each unit consists of one share of common stock (or one pre-funded warrant in lieu thereof), a common warrant to purchase one share of the company’s common stock with a term of 24 months from the issuance date, and a common warrant to purchase one share of the company’s common stock with a term of 66 months from the issuance date. Each common warrants will be exercisable beginning six months following the closing date, at an $2.062/share exercise price. Each pre-funded warrant has an exercise price of $0.001 per share and does not expire until

For further details see:

HTG Molecular Diagnostics slips on $7.5M private placement